News

Ruth Potee, M.D., of Greenfield, Mass., said that when buprenorphine first became available in 2002, there was an expectation that it would be widely used in primary care because addiction is a chronic condition. “By 2010, only 2 percent of primary care physicians were prescribing it,” she said. “That was a massive failure.” Dr. David…

Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. Dr. Raffa is a global leader in pharmacology, with over 40 years of preclinical research on drug abuse and analgesic drug discovery. He has held many prestigious leadership roles, including Co-Leader for analgesic drug discovery at Johnson…

Dr. Greg Sullivan, Chief Scientific Officer, Dr. Dave Bergstrom. Chief Operations Officer, and Tim Peara of will be speaking about how Bridge Therapeutics’ lead investigational drug could be a key part of ending the opioid crisis. Each year 70 million Americans will take an opioid for pain. Of these, 17 million take a strong opioid…

“A great part of the tragedy of this opioid crisis is that, unlike in previous such crises America has seen, we now possess effective treatment strategies that could address it and save lives,” Nora Volkow, MD, the director of the National Institute on Drug Abuse, wrote in an editorial accompanying the study (Ann Intern Med 2018…

In this article the Washington Examiner discusses how buprenorphine/naloxone combination should be readily available and could act as a key defense against the on going opioid problem in the U.S. Key to understanding how buprenorphine helps is an understanding of the difference between physical dependence and addiction. This can be a confusing distinction, as the…

In this article “Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities,” Sarah Wakeman, MD, medical director of the Massachusetts General Hospital Substance Use Disorders Initiative and Michael Barnett, MD, of the Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, discuss how “to have any hope of stemming…

In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria. Cathy Cahill PhD, a pain researcher at UCLA also explains how those with chronic pain taking traditional opioids experience big swings of emotion due to the euphoria and subsequent dysphoria…

America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in the labor force, are taking painkillers of some kind,”…

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals. Alton Kelley, Director…

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York. More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life…